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Abstract
Phagolysosome fusion and granule exocytosis in neutrophils are calcium-dependent processes. The calcium requirements vary between
granule types, suggesting the presence of different calcium sensors. The synaptotagmins, a family of calcium-binding proteins, previously
shown to participate in vesicle fusion and vesicle recycling in excitable cells, are putative calcium-sensors of exocytosis in excitable cells. In
this study, we show that synaptotagmin II is present in human neutrophils and may participate in phagocytic and in exocytotic processes. In
protein extracts from human neutrophils, we identified synaptotagmin II by Western blot as an 80 kDa protein. Subcellular fractionation
revealed that synaptotagmin II was associated with the specific granules. In fMLP-stimulated cells, synaptotagmin II translocated to the
plasma membrane. This correlated with the upregulation of complement receptor 3 (CR 3), reflecting the translocation of specific granules to
the cell surface. Synaptotagmin II also translocated to the phagosome after complement-mediated phagocytosis in the presence of calcium.
LAMP-1 translocated in parallel but probably was located to another subcellular compartment than synaptotagmin II. Under calcium-reduced
conditions, neither synaptotagmin II nor LAMP-1 translocated to the phagosome. We therefore suggest a role for synaptotagmin II as
calcium-sensor during phagocytosis and secretion in neutrophils. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Neutrophils form the first line of defence in the host
response to invading bacteria. The secretion of granule
contents to the exterior or into the phagosome represents
important means by which the neutrophil ingests and kills
invading microorganisms. Calcium is important for many
functions in the neutrophil such as chemotaxis [1], Fc-
receptor mediated phagocytosis [2] and activation of the
NADPH oxidase [3]. Secretion of neutrophil granules is also
a calcium-dependent event and different granule populations
have distinct Ca2 + requirements for secretion [4–7]. The
MPO-containing granules are only secreted at high Ca2 +
concentration, while secondary granules are secreted in
response to lower Ca2 + concentrations [4]. This suggests
the requirement for several calcium sensors responsible for
mobilisation of the different granules.
Phagocytosis can take place in the absence of calcium
[2] but after phagocytosis, Ca2 + rises locally around the
phagosome [8]. The fusion of secondary granules with the
neutrophil phagosome is a calcium-dependent event [9].
For phagolysosome fusion to take place, the periphagoso-
mal actin network has to be severed, which again is a
calcium-dependent event [9,10]. The link between calcium
and these crucial events for the neutrophil clearly shows
the need for several calcium-sensing targets, functionally
activated through a very large range of calcium concen-
trations.
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The SNARE hypothesis proposes a molecular mecha-
nism regulating the docking of vesicles and fusion of
membranes, leading to synaptic secretion [11,12]. The
hypothesis has been extended to other secretory cells such
as chromaffin cells in the adrenal medulla [13], pancreatic
h-cells [14] and kidney cells [15]. The SNARE-hypothesis
implies that a vesicle bound protein, a v-SNARE (vesicle
membrane-SNAP receptor), is bound to a t-SNARE (target
membrane SNAP receptor) on the target membrane [11,12].
To form a high-affinity SNARE-complex, another protein is
needed, SNAP-25/23 (synaptosome-associated protein)
[16]. This complex also binds a/h SNAP (soluble NSF
attachment proteins) that interact with an ATPase called
NSF (N-ethylmaleimide-sensitive fusion protein) [11,12].
The presence and function of some proteins of the
SNARE-complex have also been shown in neutrophils. A
v-SNARE (VAMP2) and several t-SNAREs called syntaxins
have been found [17–20] as well as SNAP 23, 23B and 25
[20,21], and it was recently shown that VAMP3 accumu-
lated to the phagosome [22].
The suggested major calcium sensor for neuronal and
neuroendocrine secretion are the synaptotagmins, a family
comprising of at least 11 proteins. The best-characterised
protein of the family is synaptotagmin I, whereas the
functions of the other members are less clear. Drosophilia
and C. elegans mutants lacking synaptotagmin I show a
drastically impaired neurotransmission [23,24] and the syn-
aptotagmin I knockout mice suffer from early neonatal death
and impaired neurotransmission [25]. The synaptotagmins
have a short intravesicular N-terminal segment, a mem-
brane-spanning region, a cysteine-rich region, two C2
domains able to bind calcium and acidic phospholipids
and finally a conserved region at the C-terminus [26,27].
The proteins have different calcium affinities regulating
their binding to phospholipids, syntaxin and for homo-
and heterodimerisation [28–30].
Several other calcium-binding proteins like annexins are
present in neutrophils [5], and may play a role in exocytosis
[31]. They are able to induce fusion of granules in vitro [32]
and could therefore play a role in the late steps of exocytosis
and phago-lysosome fusion. However, their relationship to
the SNARE-complex is not established. Here we investi-
gated the presence, subcellular localization and role of
synaptotagmin II in human neutrophils during exocytosis
and phagocytosis.
2. Material and methods
2.1. Materials
Percollk, ECL, Hybond ECL nitrocellulose membranes
and 57Co was purchased from Amersham Pharmacia
Biotech AB, Uppsala, Sweden and Polymorphprepn,
Lymphoprepn from Nycomed Pharma AS, Oslo, Norway.
Toluidine blue and Diisopropylfluorophosphate (DFP) were
obtained from Fluka Chemie AG, Buchs, Switzerland and
the VIP Kit from Vector Laboratories, Burlingame, CA,
USA. Pefabloc, pepstatin, aprotinin and leupeptin were
bought from Roche Diagnostics, Stockholm, Sweden.
ATP(Na)2, PIPES, DFP and PMSF was obtained from
Sigma-Aldrich, 8G2b monoclonal anti-synaptotagmin II
antibody raised against a synthetic peptide of the N-terminal
sequence of rat synaptotagmin was a kind gift of Dr.
Masami Takahashi, Mitsubishi Kasei Institute of Life Sci-
ences, Japan. Rabbit anti-LAMP-1 antibody was a kind gift
from Dr. Sven Karlsson, Umea˚ University, Sweden. Anti-
bodies for the gelatinase-ELISA were a kind gift from Drs.
Lars Kjeldsen and Niels Borregaard, The Finsen Center, The
National University Hospital, Copenhagen, Denmark. Alexa
fluor 594/488-goat-anti-mouse H +L and Alexa fluor 488-
goat-anti-rabbit H + L were produced by Molecular Probes
Eugene, OR, USA and normal goat serum, normal rabbit
serum, anti-human iC3b receptor antibody conjugated to R-
phycoerythrin, goat anti mouse-HRP, mouse IgG and 1,2-
phenylenediamide dihydrochloride (OPD) by DAKO-
PATTS, Glostrup, Denmark.
2.2. Separation of neutrophils
The neutrophils were obtained from heparinized blood
from healthy donors and separated from other white blood
cells with Polymorphprepn on a density gradient. Eryth-
rocytes were eliminated by hypotonic lysis. Neutrophils for
subcellular fractionation were obtained by dextran sedimen-
tation followed by hypotonic lysis to eliminate erythrocytes
and thereafter Ficoll-Paquen gradient centrifugation to sep-
arate neutrophils from other white blood cells. Cells were
then resuspended in Krebs–Ringers Glucose buffer (KRG)
containing 120 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO4,
8.3 mM KH2PO4, 10 mM glucose and 1.0 mM CaCl2. For
calcium-buffered conditions, KRG without CaCl2 was used
and 1 mM EGTA and 25 AM of MAPTAM added for 30
min at 37 jC.
2.3. Preparation of mastcells
Peritoneal mastcells were obtained from Sprague–Daw-
ley rats and were prepared as earlier described [33]. In
brief, a peritoneal wash solution with 0.1% bovine serum
albumin in phosphate buffered saline (PBS), pH 7.3, was
applied on a three-step Percolln gradient of 30%, 50% and
90% and centrifuged at 600 g for 20 min at 4 jC. The
pellet was then washed in PBS and the content of mastcells
was assessed with toluidine blue. The purity of mastcells
was z 90%.
2.4. Membrane preparation of rat brain
Brain tissue from Sprague–Dawley rats were homoge-
nised in a Tris–sucrose buffer (0.32 M sucrose, 5 mM Tris,
1 mM EGTA, 1 mM 2-mercaptoethanol) containing protei-
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nase inhibitors (0.01 mg/ml leupeptin, 0.01 mg/ml aprotinin,
0.0014 mg/ml pepstatin, 1 mM PMSF) washed and centri-
fuged at 1000 g for 10 min to remove fat and nuclei.
Thereafter, the pellet was resuspended in the Tris–sucrose
buffer and centrifuged at 30,000 g for 60 min. The
resulting pellet was resuspended in Tris buffer (same as
above but without sucrose) and used as a positive control for
synaptotagmins in electrophoresis experiments.
2.5. Subcellular fractionation
Subcellular fractionation was carried out essentially as
described in the review by Kjeldsen et al. [34]. In short,
peripheral neutrophils were isolated from buffy coats and
were treated with diisopropylfluorophosphate (DFP) (8
Amol/l) to inhibit protease activity and thereafter resus-
pended in a disruption buffer (100 mM KCl, 3 mM NaCl,
3.5 mM MgCl2 6 H2O, 10 mM PIPES, 1 mM ATP(Na)2
and 0.5 mM PMSF). The cells were disintegrated by
nitrogen cavitation for 5 min at 400 psi in a nitrogen
bomb (Parr Instruments, Moline, IL, USA). Nuclei and
intact cells were pelleted by centrifugation at 400 g for
15 min. The supernatant was put on a three-step Percoll
gradient (1.05, 1.09 and 1.12 g/ml) and centrifuged at
38,000 g for 25 min. The gradient was collected in 1.5
ml fractions and analysed for markers of the different
granules. Myeloperoxidase (MPO; marker for azurophilic
granules) was determined by hydrolysis of its substrate
OPD as described by the manufacturer and vitamin B12
binding protein (marker for the specific granules) was
determined by a cyanocobalamin technique as described
by Gottlieb [35]. Alkaline phosphatase (ALP; marker for
the secretory vesicles and plasma membrane) was meas-
ured by cleavage of p-nitrophenyl phosphate according to
the method of DeChatelet and Cooper [36] and gelatinase
was measured using an ELISA method [37] to determine
the localisation of gelatinase containing organelles in the
gradient.
2.6. Western blots
Mastcells or neutrophils were suspended in a disruption
buffer (150 mM NaCl, 50 mM HEPES pH 7.4, 10 mM
EDTA, 2 mM EGTA, 1% Triton-X 100, 0.1% SDS, 50 mM
NaF, 10 mM sodium pyrophosphate, 2 mM Na3VO4, 2 mM
Pefabloc and 20 AM leupeptin) and then centrifuged at
11,500 g for 15 min at 4 jC. The supernatant was mixed
with 5 sample buffer (60 mM Tris–HCl pH 6.8, 25%
glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, 0.1% brom-
phenol blue) and boiled for 5 min. Unsolubilised material
was spun down at 15,800 g for 5 min at 4 jC. Extracted
material from 106 cells was loaded in each well of a 8% or
10% SDS-acrylamide gel. Proteins were separated and
immobilized on to nitrocellulose membranes and were there-
after blocked with Tris-buffered saline (TBS: 20 mM Tris,
140 mM NaCl, pH 7.6) containing 0.05% Tween-20 and 5%
milk, incubated with primary antibody (1:2000 in TBS) and
thereafter either incubated with a secondary antibody con-
jugated to horseradish peroxidase (HRP) (1:2500 in TBS)
and developed either with ECL or by adding a peroxidase
substrate that directly stains the membrane (VIP Kit).
2.7. Immunofluorescence
Neutrophils (1106) in KRG with or without Ca2 +
were allowed to adhere to glass coverslips for 20 min at 37
jC. An equal amount of yeast opsonised with normal
human serum was added and the samples were incubated
at 37 jC for 12 min. Cells were fixed in 3% paraformalde-
hyde (PFA) for 15 min, washed three times in KRG and
permeabilised with 0.3% Triton X-100 for 45 s. Cells were
washed and incubated with primary antibody in PBS pH 7.3
with 1.8% BSA and 10% serum from the secondary anti-
body species for 1 h in 37 jC. Cells were washed and
incubated with fluorescent secondary antibody diluted 1/200
or 1/300, washed again and mounted for microscopic
observation. When preparations were double labelled, the
cells were first incubated with anti-synaptotagmin II anti-
body and washed as above and then incubated with the
second primary antibody. Both secondary antibodies were
added together for the last incubation. Controls were pre-
formed with both primary antibodies in single labelling to
ensure that the same results could be obtained as with
double labelling. Imaging was performed in a Sarastro
2000 confocal microscope (Molecular Dynamics, Sunny-
vale, CA) equipped with dual detectors and a Nikon micro-
scope with a  60, NA 1.4 oil immersion objective. The
488 and 514 nm lines of the Argon laser were used
together for simultaneous excitation of Alexa488 Fluor
and Alexa594 Fluor. Dichroic mirrors with cut-off wave-
lengths of 535 and 595 nm were employed for the excited
and emitted light, respectively. A 545DF30 nm band-pass
filter was employed for detection of the green signal
(Alexa488 Fluor) and a 600 nm long-pass emission filter
was used for detection of the red signal (Alexa594 Fluor).
This filter set-up ensured no detection of the red signal in
the green channel or vice versa.
2.8. Flow cytometry
Fifty microliters of whole blood was incubated with
fMLP (10 7 M) at 37 jC for indicated times. The samples
were then incubated for 30 min on ice with 5 Al of R-
phycoerythrin conjugated anti-human CD11b receptor anti-
body. The erythrocytes were then lysed for 5 min at 15 jC
in an ammonium-containing buffer (150 mM NH4Cl, 1 mM
KHCO3, 0.1 mM EDTA). The remaining white blood cells
were pelleted and resuspended in 0.1% PFA. The samples
were then analysed in a Becton-Dickinson FACS-calibur.
Gates were set to exclude erythrocytes, monocytes and
lymphocytes. Mean fluorescence of at least 5000 gated cells
were determined.
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3. Results
3.1. Presence of synaptotagmin II in human neutrophils
The presence of synaptotagmin II was investigated using
a monoclonal antibody, 8G2b raised against the N-terminal
of synaptotagmin II. In rat brain preparations, the antibody
8G2b reacted with two bands, of approximately 60 and 120
kDa, respectively (Fig. 1a). The lower band is close to the
previously reported molecular weight for synaptotagmin II
(66 kDa) [38]. The 120-kDa band could therefore be a dimer
of synaptotagmin II. In neutrophils, the antibody reacted
with a band of about 80 kDa but not with any bands of 60 or
120 kDa (Fig. 1a). Interestingly, the same antibody has
previously been showed to detect an 80-kDa synaptotagmin
II band in mastcells. By transfecting synaptotagmin II into
RBL-cells, Nishiki et al. [44] showed that the gene product
had an increased molecular weight in these cells, which
could be due to posttranslational modifications or alternative
splicing during myeloid differentiation. The anti synapto-
tagmin II antibody 8G2b reacted with proteins of similar
molecular weight of 80 kDa both in mastcells and in
neutrophils (Fig. 1b). The molecular mass of synaptotagmin
II changed from 80 to 70 kDa in the absence of 2-
mercaptoethanol, that is under nonreducing conditions (data
not shown).
3.2. Subcellular localisation of synaptotagmin II
Different granule populations in the neutrophil are
secreted in response to different calcium concentrations
[4–7]. Since members of the synaptotagmin family bind
to the SNARE complex and phospholipids at different levels
of calcium [28–30], they could be responsible for the
different calcium requirements for degranulation of the
various granule populations. We therefore determined the
subcellular localization of synaptotagmin II in the neutro-
phil. In order to separate the different granule populations, a
three-layer Percoll gradient was used (Fig. 3). The azurophil
granules were recovered in the dense part of the gradient
(fractions 2–5). The specific granules, identified by their
content of vitamin B12-binding protein and (partly) gelati-
nase, was located in fractions 11–13 while the gelatinase
granules, marked by their content of gelatinase and absence
of vitamin B12-binding protein, were recovered mainly in
fractions 16–18. The alkaline phosphatase-containing secre-
tory vesicles and plasma membrane were found in the upper
part of the gradient (fractions 20–23). The cytosol was
found in fractions 25–36 (not shown on blot). Western blot
analysis of all fractions with anti-synaptotagmin II antibody
showed that the synaptotagmin II colocalised with the
granules containing vitamin B12 binding protein and gelat-
inase, i.e. the specific granules (Fig. 2). There was no
detectable synaptotagmin II in the azurophilic granules or
plasma membrane/secretory vesicle fractions.
3.3. Translocation of synaptotagmin II after phagocytosis
and fMLP stimulation
In order for synaptotagmin II to be involved in phag-
olysosome fusion or secretion, it needs to translocate to the
phagosome and plasma membrane, respectively. We there-
fore investigated the distribution of synaptotagmin II before
and after phagocytosis and before and after secretion
induced by fMLP stimulation.
To study the protein distribution, the cells were stimulated
with fMLP (10  7 M) for 2, 5 or 10 min. Control cells
warmed to 37 jC for the same periods of time showed a
weaker granular fluorescence for synaptotagmin II, which
was evenly distributed throughout the cytoplasm. After
neutrophil stimulation with fMLP, the synaptotagmin II was
localised to structures in close proximity to the plasma
membrane (Fig. 3). To more objectively look at this, pixel
intensity was measured at the edge of the cell and the mean
was compared to themean pixel intensity of the whole cell. At
10 min, when the largest translocations could be seen, fMLP-
stimulated cells had a mean ratio (edge to whole cell) of 1.93
compared to the unstimulated cells which had a ratio of 1.44.
If synaptotagmin translocation reflects degranulation of
specific granules, the process should lead to release of
Fig. 1. (a) The presence of synaptotagmin II in human neutrophils and rat
brain. Material from f 106 neutrophils (PMN) and 3 Ag of rat brain
membrane (RBM) were loaded on a 10% acrylamide gel and then
transferred to nitrocellulose. The membrane was then incubated with the
anti synaptotagmin II antibody, 8G2b (n = 3). (b) The presence of
synaptotagmin II in human neutrophils and in rat peritoneal mastcells.
Material from f 106 neutrophils (PMN) and material from about f 106
mastcells (MAST) was separated on a 8% acrylamide gel and then
transferred to nitrocellulose membranes. The antibody 8G2b revealed the
presence of Syt II with a molecular weight of 80 kDa in protein extract from
both tissues (n= 3).
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granulae contents and upregulation of certain receptors, e.g.
the CR3 localised in the specific and gelatinase granules in
resting cells [39]. In parallel with confocal experiments of
neutrophils stimulated with fMLP, upregulation of CR 3 was
studied with flow cytometry. Upregulation of CR 3 has been
studied earlier [39–41] and could in our experiments be
Fig. 3. Translocation of synaptotagmin II to the plasma membrane of human neutrophils after fMLP stimulation. Immunofluorescence was carried out with anti
synaptotagmin II antibody. In panels A–C, cells were stimulated with fMLP in a concentration of 10 7 at 37 jC for the indicated times. Panels D–F: control
cells were incubated in KRG for the same time as fMLP-stimulated cells. Stimulation was ended by addition of 4% ice-cold PFA. A representative experiment
of three experiments is shown.
Fig. 2. The subcellular localisation of synaptotagmin II in human neutrophils. Subcellular fractionation was carried out on a Percoll gradient and the fractions
were blotted with the anti synaptotagmin II antibody, 8G2b. Upper panel: All fractions were analysed for the presence and amount of the granule markers
myeloperoxidase (primary granules), vitamin B12 binding protein (specific granules), gelatinase (tertiary granules) and alkaline phosphatase (secretory vesicles
and plasma membrane). Lower panel: A band of a molecular weight of about 80 kDa was present in fractions 10–12 (n= 3).
I.M. Lindmark et al. / Biochimica et Biophysica Acta 1590 (2002) 159–166 163
seen already after 2 min and continued for at least 10 min
(results not shown) correlating with the time course of
synaptotagmin II translocation in fMLP stimulated neutro-
phils in the confocal experiments (Fig. 3).
During phagocytosis, neutrophil granules translocate to
the phagosome and fuse with its membrane. In nonphago-
cytosing neutrophils, synaptotagmin II was distributed in an
even granular pattern. After phagocytosis of complement-
coated yeast particles, synaptotagmin II translocated to the
periphagosomal area and was seen as an irregular ring
enclosing the whole phagosome (Fig. 4). This correlated
with the translocation to the phagosome of another protein
LAMP-1, which is present in multivesicular bodies and a
marker of phagosome maturation (Fig. 4) [42]. However,
the staining pattern of the two proteins in the vicinity of the
phagosome as well as in the cytoplasm was different. This
supports earlier observations of the two proteins probably
residing in different membrane compartments [42]. In Ca-
depleted cells phagocytosing complement-coated yeast, no
translocation to the phagosome could be seen.
4. Discussion
Neutrophil granules fuse with the plasma membrane or
with the phagosomal membrane in a Ca2 + -dependent man-
ner, each granule type fusing at different Ca2 + concentra-
tions [4–7]. This fusion does not only lead to secretion and
receptor upregulation but may also be a prerequisite for
pseudopod formation and phagocytosis [9,43]. Recent evi-
dence suggests that neutrophils like neuronal and endocrine
cells use the SNARE-complex to achieve membrane fusion
[19]. Synaptotagmin I and II are able to interact both with
phospholipids and proteins of the SNARE-complex in a
calcium-dependent way [28–30] and are therefore attractive
candidates for regulating calcium-dependent fusion pro-
cesses also in neutrophils. Here we show that an 80-kDa
synaptotagmin II is present on the specific granules in
neutrophils. The molecular weight correlates well with other
syt II proteins found in myeloid cells or cell lines [38] but
not with the 60-kDa protein found in rat brain. To show that
the synaptotagmin-containing organelles are functional, we
investigated their translocation during cell activation. Two
models were chosen, (i) granule fusion with the plasma
membrane after stimulation with fMLP and (ii) granule
fusion with the phagosome after complement-opsonized
yeast ingestion. As a marker for fMLP-induced exocytosis
of specific and gelatinase granules, the upregulation of CR3
on the plasma membrane was monitored by FACS analysis.
CR3 is present in specific and gelatinase granules [39] and
indeed synaptotagmin II translocated towards the plasma
membrane in parallel with CR3 upregulation.
Fig. 4. Translocation of LAMP-1 and synaptotagmin II to the phagosome of human neutrophils. Neutrophils were allowed to phagocytose yeast particles for 12
min. They were then fixed and first labelled with anti-synaptotagmin II antibody followed by anti-LAMP-1 antibody. Controls (not shown) with single labelling
using either primary antibody ensured that the same translocation could be seen individually. Panels A and B shows a neutrophil phagocytosing yeast when
calcium is present. Panel A shows the distribution of anti-synaptotagmin II antibody and panel B the distribution of anti-LAMP-1 antibody. Panels C and D
shows a neutrophil phagocytosing under calcium-buffered conditions. The pattern of synaptotagmin II distribution is shown in panel C and the distribution of
LAMP-1 in panel D. The stars indicate the phagosomes (n= 3).
I.M. Lindmark et al. / Biochimica et Biophysica Acta 1590 (2002) 159–166164
Several types of neutrophil granules are translocated to
the phagosome and fuse with the phagosomal membrane
during phagosome maturation. In most cells, LAMP-1
(lysosome-associated membrane protein) is found in lyso-
somal membranes. The primary granules of neutrophils are
analogous to lysosomes, but they do not contain LAMP-1
[42,44]. Instead, LAMP-1 has been found in multilaminar
compartments, which also translocate to the phagosome
[42]. Therefore, LAMP-1 served as a marker for the trans-
location process towards the phagosome. Synaptotagmin II
translocated to the phagosome in parallel with LAMP-1,
suggesting that the synaptotagmin-containing organelle par-
ticipates in phagosome maturation.
The role of synaptotagmin II can at this time only be
speculated upon. We cannot exclude that synaptotagmin is
just a cargo of the granule membrane with no involvement
in granule fusion. However, this possibility appears unlikely
for a number of reasons. (i) The role of synaptotagmin in
neuronal secretion is well documented even if the exact
mechanism is not yet clear, and SNARE proteins are also
involved in neutrophil secretion. Preliminary experiments
also indicate that synaptotagmin II coprecipitates with
certain SNARE proteins (I. M. Lindmark et al., manuscript
in preparation); (ii) the specific granules are secreted to the
exterior of the cell at a calcium concentration of 1–5 AM [4]
and synaptotagmin II binds phospholipids in the same
calcium concentration range [30]; (iii) synaptotagmin I
and II were shown to be involved in Ca2 + -mediated
exocytosis in mastcells that are of myeloid origin like
neutrophils. Synaptotagmin II acted as an inhibitor of
Ca2 + -induced exocytosis of a lysosomal compartment
whereas synaptotagmin I enhanced release of a different
granule type [38,45]. In neutrophils, synaptotagmin II is
located in a distinct granule compartment and is absent from
the azurophilic granules which resemble lysosomes. Other
synaptotagmins or other calcium-dependent proteins are
probably present in other neutrophil granules, which
explains their distinct Ca2 + requirements for exocytosis.
Preliminary experiments with antibodies against synapto-
tagmin I, III and IV failed to consistently identify the
respective proteins in neutrophils. Our data do not rule out
the involvement of other calcium sensors, but clearly
indicate that one of the major calcium sensors in late steps
of neuronal secretion, i.e. synaptotagmin II, is present in
human neutrophils and could be operative in granule fusion.
In conclusion, we show for the first time that synapto-
tagmin II, a presumed Ca2 + sensor of neuronal secretion, is
present on specific granules in human neutrophils. Its
subcellular localisation and its documented role in other
cells suggest that it participates in the Ca2 + regulation of
neutrophil exocytosis and phagolysosome fusion.
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